Tuesday, November 20, 2007
Ethical "Embryonic" Stem Cells from Your Skin
Posted by
Bayman
at
12:49 PM
4
comments
Labels: embryonic stem cells
Monday, October 15, 2007
Fresh Science at Nature Precedings
Posted by
Bayman
at
12:47 AM
1 comments
Labels: embryonic stem cells, reprogramming
Thursday, August 30, 2007
Another blow to the stem cell hypothesis
In fact this article quotes the researchers as saying:
[BrdU is] ... "a very insensitive and nonspecific marker."
and
"This study suggests that researchers should test BrdU label retention as a marker before assuming it can be used to identify stem cells in other tissues"
Posted by
Anonymous Coward
at
6:25 AM
0
comments
Labels: brdu, embryonic stem cells, immortal strand
Tuesday, August 21, 2007
Histone Code Cracked?
I once proposed a similar project in a mock post-doc grant proposal for a systems biology grad class I took (except with the added minor step of cloning mice by somatic cell nuclear transfer). It got pretty bad reviews. Apparently some people thought it was too ambitious. Go figure. This one only took 15 authors...
Posted by
Bayman
at
7:52 PM
2
comments
Labels: embryonic stem cells, epigenetics, histone code, progenitors
Monday, June 25, 2007
Introducing: bayblab definitions
functional definition:
-ability for self-denial
-ability to solve differential equations
see also: transit-pimping cells, commited prudo-genitals and terminally disoriented cells.
Posted by
Anonymous Coward
at
2:54 PM
2
comments
Labels: embryonic stem cells, schmeroids, spheroids, stem cell
Monday, June 11, 2007
New stem cell journal from "Cell"
It was bound to happen, cell, the top tier journal when it comes to cell biology spun off a new journal dedicated to stem cells last week. It took a few days for the university to get access, but I was finally able to peruse it today. I had a little bit of a double take actually regarding the landmark paper published in this first edition. You may have heard that Myc, sox2, oct4 and klf4 are sufficient to reprogram fibroblasts into stem cells. In fact you may have heard of it a full year ago, as this experiment was done by a Japanese group (Takahashi K, Yamanaka S.) and published in Cell. This new paper seems to be almost the same experiments except it takes 12 American scientists to do the work of 2 Japanese :). And if that wasn't confusing enough, another team from the Whitehead Institute also published similar findings last week in nature. This latter group is a proponent of the bivalent histone code regulation of key stem-cell factor. The idea is that both repressive and active histone modifications mark the promoters of these factors making them easily inducible but also primed for repression may the cell wish to differentiate. As talked about previously on the bayblab, these bivalent promoters may be suceptible to dysregulation by epigenetic factors (trithorax/polycomb) over time and may be one of the mechanisms to transformation...While we have talked about sox2, klf4, c-myc and oct4 when the first paper came around there are a few things worth highlighting this time around... While the ectopic expression of these transcription factors is required for the reprogramming it is not really sufficient. There was a large lag period between the expression and the reprogramming, suggesting there is an additional stochastic event that needs to occur. Also, c-myc is the odd one of these transcription factor as it tends to regulate very large areas of chromatin rather than just specific genes. Perhaps the lag is due to chance remodelling event over large areas. For example the authors show that the inactive X chromosome is re-activated by these factors. So this begs the question: what happens to the chromatin, how is the histone code changed, what is the lag for, would expression of members of the trithorax/polycomb make the process more efficient?
More on that later....
Posted by
Anonymous Coward
at
10:57 AM
3
comments
Labels: c-myc, Cell journal, embryonic stem cells, klf4, oct4, sox2
Monday, May 07, 2007
Embryonic Stem Cells (tm) by Invitrogen
Caught a great talk today at the OHRI by visiting speaker Mahendra S. Rao, who is probably the world's leading scientist in embryonic/neural stem cell therapies. The talk featured an overwhelmingly impressive wealth of data on neural stem cell biology, particularly pertaining to transplant studies. Most of this work was done in his former capacity as head of the NIH's stem cell program.What was most interesting about the talk was the work Rao is now leading as VP Stem Cell research at Invitrogen Corp (in the more ES-cell research friendly state of California). He recently took up this post after leaving the NIH as a result of their decision to abandon ES cell research in light of the Bush administration's strong anti ES cell research policies. From what he presented of his new project at Invitrogen, it's obvious they are now about to kick some serious ass in the arena of clinical therapeutic development. They've got GMP-friendly, FDA-approved and production-scalable technologies and ES cell lines ready to go. Couple with that Invitrogen's recent moves that has established the company as the leader in gene expression and cell culture technologies, and what you have is imminent domination of the biological therapies scene. Looks like one of the first applications they will go after is Parkinson's disease, using ES-derived neurons to replenish dopamine producers in the substantia nigra.
Interestingly, while transplanted ES-derived neurons are suitable for applications such as Parkinson's as they can survive long-term in recipient's brain, Rao mentioned that their potential in other regenerative therapies is limited by the fact that we do not yet know how to make the transplanted cells properly integrate into existing neuronal circuitry. Strong impetus for a lot of interesting research in probing neural connectivity...
Posted by
Bayman
at
6:59 PM
14
comments
Labels: biolgical therapy, brain, embryonic stem cells, George Bush, invitrogen, neural stem cells, NIH, therapeutics

Podcast




4 comments:
Post a Comment